|
|
|
| Effects of Alprostadil combined with Edaravone on Coagulation Function, Levels of Plasma cTnI Hcy and PCT and Neurological Function in Patients with Acute Cerebral Infarction Complicated with Hypertension |
| LI Li, WEN Xia |
| People's Hospital of Inner Mongolia Autonomous Region, Inner Mongolia Hohhot 010010, China |
|
|
|
|
Abstract Objective: To explore the effects of alprostadil combined with edaravone on coagulation function, levels of plasma troponin I (cTnI), homocysteine (Hcy) and procalcitonin (PCT) and neurological function in patients with acute cerebral infarction (ACI) complicated with essential hypertension (EH). Methods: 126 patients with ACI+EH were prospectively studied and randomly grouped (observation group, n=63; control group, n=63). All patients were given conventional symptomatic basic treatment, and control group was given edaravone, and observation group was given alprostadil based on above treatment. The coagulation function indexes, levels of plasma cTnI, Hcy and PCT and neurological function were observed in the two groups before treatment and after 14 d of treatment. The adverse reactions of the two groups were evaluated. Results: After treatment, the activated partial thromboplastin time (APTT), thrombin time (TT) and prothrombin time (PT) were significantly shortened, the contents of D-dimer (DD) and fibrinogen (Fib) were significantly decreased (P<0.05), the levels of plasma cTnI, Hcy and P CT were significantly decreased (P<0.05), and the scores of neurological deficit scale (mNIHSS) were significantly decreased (P<0.05) and the levels of serum S100B were significantly decreased in both groups (P<0.05). The change range in the observation group was significantly larger than that in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between groups (P>0.05). Conclusions: Alprostadil combined with edaravone can effectively improve the coagulation function of ACI + EH patients, alleviate craniocerebral injury and neurological function damage, and is beneficial to the prognosis of patients. It is safe and effective in clinical application.
|
|
|
|
|
|
[1] 王广慧,冯敏.脑钠肽及N端脑钠肽前体与急性脑梗死的相关性研究进展[J].安徽医学,2017,38(2):250~253.
[2] 宋燕峰,吴朝霞,刘红,等.H型高血压与急性脑梗死的相关性研究[J].内科急危重症杂志,2016,22(1):17~18.
[3] 石健,赵钢,程春生,等.前列地尔对皮瓣移植患者术后凝血系统的影响[J].创伤外科杂志,2016,18(9):560~562.
[4] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志,2010,2(2):16~19.
[5] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579~616.
[6] 刘玉府,王利红.人尿激肽原酶联合血小板抑制剂对高血压脑梗死大鼠凝血功能及神经功能的影响[J].中华实验外科杂志,2016,33(6):1597~1600.
[7] 李璠,陈伟伟,赵晓姝,等.依达拉奉联合灯盏花素对脑缺血大鼠大脑皮质MCP-1的影响[J].中国临床解剖学杂志,2018,36(1):38~44.
[8] 陈锋.血浆CTnⅠ,HCY和PCT水平对急性颅脑损伤患者的早期诊断、严重程度和预后评价的临床意义[J].标记免疫分析与临床,2014,21(6):703~705.
[9] 安占军,徐立霞,曹洁玮.脂微球前列地尔联合依达拉奉治疗急性脑梗死疗效探讨[J].武警医学,2017,28(5):475~477. |
| [1] |
. [J]. 河北医学, 2017, 23(9): 1515-1518. |
|
|
|
|
2019, Vol. 25 
